AI and Patient Safety: A New Compliance Challenge for Pharmaceutical Companies

Imagine this: a patient asks an artificial intelligence (AI) tool how to take a prescribed medication. The AI confidently suggests a dosage, lists benefits or even hints at unapproved uses. However, it fails to mention risks, side effects or the patient’s medical history. The result? Potentially life-threatening outcomes. This is not science fiction, it’s happening now. AI tools are becoming trusted sources for millions seeking quick health answers. But the issue is AI tools don’t operate under the same strict regulations as doctors, pharmacists or pharmaceutical companies.

Pharmaceutical companies are bound by rigorous compliance standards. For instance, in the UK the Prescription Medicines Code of Practice Authority (PMCPA) that companies provide a “fair balance” of benefits and risks in all drug-related communications. AI, however, doesn’t follow these rules. Instead, its responses are generated by pulling data from various sources, some reliable, others not, and often it gets things wrong. 

The Risks of AI-Generated Health Advice

AI’s ability to “hallucinate” (fabricate or guess information) is well-documented. Not so bad if you’re being recommended a restaurant that closed a year ago. Very bad if you’re asking about a prescription medicine. AI often strips away critical context, such as safety warnings or contraindications, in an attempt to deliver concise answers. Worse, it might suggest off label uses (unapproved applications of a drug), which can jeopardize patient safety and leave pharmaceutical companies liable. For example, if a patient misuses a drug based on AI-generated advice and suffers harm, regulators may hold the pharmaceutical company accountable. This creates a nightmare scenario for the industry, where misinformation spread by AI could lead to lawsuits, reputational damage and regulatory penalties.

Regulators Are Tightening the Screws

Regulatory bodies are beginning to address the challenges posed by AI. In the UK, the PMCPA now insists that pharmaceutical companies correct online misinformation about their products, even if they didn’t create it. Similarly, in the United States and Europe, emphasize that companies remain responsible for ensuring accurate and compliant information, even when AI tools are involved. The message is clear: pharmaceutical companies cannot ignore AI-driven misinformation. Ignorance is not a defense.

The Path Forward: Adapting to AI in Healthcare

As generative AI reshapes how information is created, shared and consumed, pharmaceutical companies face a pivotal moment. The rise of AI is not just a technological shift: it’s a leadership and governance challenge. Here’s how the industry can adapt:

1. Embrace AI Governance
   Pharmaceutical companies must move beyond traditional digital strategies and develop robust AI governance frameworks. This involves understanding how AI tools interact with their data and ensuring brand narratives remain accurate, balanced and compliant.
2. Proactive Risk Management
   Leaders need to anticipate scenarios where AI misinterprets or misrepresents product information. Developing clear protocols for addressing these risks is essential to safeguard patients and maintain compliance.
3. Active Monitoring
   Pharmaceutical companies must actively monitor how their products are represented across AI platforms. Misinformation must be identified and corrected swiftly to prevent harm and regulatory backlash.
4. Build Resilience
   To navigate AI-driven disruptions, companies need to invest in upskilling their teams and fostering collaboration between compliance, communications and tech departments. Resilience is key to thriving in this new era.

At Its Core: A Trust Issue

This isn’t just about compliance: it’s about trust. The pharmaceutical industry’s most valuable asset isn’t its drugs or patents, it’s the trust of patients, regulators and the public. Patients need to trust that drug information is accurate and safe. Regulators must trust that companies are doing everything possible to protect patients. And companies need to trust that their efforts won’t be undermined by rogue AI algorithms.

AI: A Force for Good or a Compliance Crisis?

The rise of AI in healthcare is inevitable. These tools have the potential to revolutionize patient care, making information more accessible and empowering people to take control of their health. However, without proper oversight, they could also create a compliance crisis and erode public trust. Pharmaceutical companies must act now. By embracing “AI-readiness,” they can turn this challenge into an opportunity for leadership. With proactive governance and a commitment to safety, they can ensure that AI becomes a force for good: empowering patients while preserving trust and compliance in the healthcare industry.